Compare VENUS REMEDIES with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs LUPIN - Comparison Results

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES LUPIN VENUS REMEDIES/
LUPIN
 
P/E (TTM) x -1.1 108.1 - View Chart
P/BV x 0.1 2.5 3.1% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 VENUS REMEDIES   LUPIN
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
LUPIN
Mar-19
VENUS REMEDIES/
LUPIN
5-Yr Chart
Click to enlarge
High Rs126986 12.8%   
Low Rs61720 8.5%   
Sales per share (Unadj.) Rs301.8369.5 81.7%  
Earnings per share (Unadj.) Rs-24.913.4 -185.5%  
Cash flow per share (Unadj.) Rs2.537.4 6.8%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs293.3303.7 96.6%  
Shares outstanding (eoy) m12.34452.49 2.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.32.3 13.4%   
Avg P/E ratio x-3.863.6 -5.9%  
P/CF ratio (eoy) x36.722.8 161.0%  
Price / Book Value ratio x0.32.8 11.3%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,154386,064 0.3%   
No. of employees `0000.917.7 5.2%   
Total wages/salary Rs m39331,513 1.2%   
Avg. sales/employee Rs Th4,026.19,453.8 42.6%   
Avg. wages/employee Rs Th425.01,782.0 23.8%   
Avg. net profit/employee Rs Th-331.8343.0 -96.7%   
INCOME DATA
Net Sales Rs m3,724167,182 2.2%  
Other income Rs m233,640 0.6%   
Total revenues Rs m3,747170,822 2.2%   
Gross profit Rs m39528,822 1.4%  
Depreciation Rs m33810,850 3.1%   
Interest Rs m3543,078 11.5%   
Profit before tax Rs m-27518,534 -1.5%   
Minority Interest Rs m0-89 0.0%   
Prior Period Items Rs m038 0.0%   
Extraordinary Inc (Exp) Rs m0-3,400 0.0%   
Tax Rs m329,017 0.4%   
Profit after tax Rs m-3076,066 -5.1%  
Gross profit margin %10.617.2 61.5%  
Effective tax rate %-11.548.7 -23.6%   
Net profit margin %-8.23.6 -227.1%  
BALANCE SHEET DATA
Current assets Rs m2,638138,536 1.9%   
Current liabilities Rs m2,30561,299 3.8%   
Net working cap to sales %8.946.2 19.4%  
Current ratio x1.12.3 50.6%  
Inventory Days Days13584 161.7%  
Debtors Days Days46112 41.2%  
Net fixed assets Rs m4,871127,516 3.8%   
Share capital Rs m123905 13.6%   
"Free" reserves Rs m3,496136,517 2.6%   
Net worth Rs m3,619137,422 2.6%   
Long term debt Rs m1,37466,417 2.1%   
Total assets Rs m7,509279,494 2.7%  
Interest coverage x0.27.0 3.2%   
Debt to equity ratio x0.40.5 78.6%  
Sales to assets ratio x0.50.6 82.9%   
Return on assets %0.63.3 19.3%  
Return on equity %-8.54.4 -192.1%  
Return on capital %1.68.9 17.8%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m059,414 0.0%   
Fx outflow Rs m51722,282 2.3%   
Net fx Rs m-51737,132 -1.4%   
CASH FLOW
From Operations Rs m51416,660 3.1%  
From Investments Rs m-123-32,825 0.4%  
From Financial Activity Rs m-3877,441 -5.2%  
Net Cashflow Rs m4-8,724 -0.0%  

Share Holding

Indian Promoters % 32.9 46.6 70.5%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 0.2 11.3 1.6%  
FIIs % 0.6 31.9 1.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 10.1 657.4%  
Shareholders   20,121 98,259 20.5%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   UNICHEM LAB  SUN PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  AUROBINDO PHARMA  

Compare VENUS REMEDIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Momentum; Sensex Trades 186 Points Higher(12:30 pm)

Share markets in India are presently trading on a strong note. Sectoral indices are trading on a mixed note with stocks in the telecom sector.

Related Views on News

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Nov 19, 2019 12:59 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - STRIDES PHARMA SCIENCE COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS